Skip to content
OpenCapital
Get started

Xeris Biopharma Holdings, Inc. XERS Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$71.5MMiss by $711.0K
EPS-$0.01Beat by $0.02
Revenue estimate$72.3M
EPS estimate-$0.03

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$90.1M
EPS estimate$0.02

Financials

Q2 2025

Income statement

See full
Revenue$71.5M+48.8%
Gross profit$59.6M+48.1%
Operating income$4.5M+155%
Net income-$1.9M+87.2%
EPS (diluted)-$0.01+90.0%

Balance sheet

See full
Cash & equivalents$59.3M+2.9%
Total debt$257.2M-4.7%
Total equity-$19.3M-0.1%
Total assets$334.7M+0.9%

Cash flow

See full
Operating cash flow$182.0K+102%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$746.32M+136%
Enterprise value$944.26M+78.7%
P/S3×+1.3×

Profitability

See full
Gross margin82.2%-1.5pp
Operating margin-4.7%-2.0pp
Net margin-13%-4.9pp

Returns & leverage

See full
Current ratio1.9×-0.3×

Segments

By product

See full
Recorlev$31.4M+136%
Gvoke$23.5M+17.1%
Keveyis$11.5M-12.5%
Royalty, contract and other revenue$3.8M+147%

Versus estimates

Revenue

Q1 2026$82.5MBeat by $2.6MQ4 2025$85.8MBeat by $3.6MQ3 2025$74.4MMiss by $11.6M
Q2 2025$71.5MMiss by $711.0K
Q1 2025$60.1MBeat by $2.5MQ4 2024$60.1MBeat by $5.2M

Diluted EPS

Q1 2026$0.01Beat by $0.01Q4 2025$0.06Beat by $0.03Q3 2025$0.00Miss by $0.01
Q2 2025-$0.01Beat by $0.02
Q1 2025-$0.06Beat by $0.01Q4 2024-$0.03Beat by $0.05

Ask the moment Xeris Biopharma Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Xeris Biopharma Holdings, Inc. report Q2 2025 earnings?
Xeris Biopharma Holdings, Inc. (XERS) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Xeris Biopharma Holdings, Inc.'s Q2 2025 revenue and EPS?
Xeris Biopharma Holdings, Inc. reported revenue of $71.5M and eps of $-0.01 for Q2 2025.
Did Xeris Biopharma Holdings, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $72.3M by $711.0K. EPS beat the consensus estimate of $-0.03 by $0.02.
How did Xeris Biopharma Holdings, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 48.8% from $48.1M a year earlier and eps grew 90.0% from $-0.10.
Where can I find Xeris Biopharma Holdings, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001867096-25-000136) directly on SEC EDGAR. The filing index links above go to sec.gov.